|
1
|
Busch J, Ralla B, Jung M, Wotschofsky Z,
Trujillo-Arribas E, Schwabe P, Kilic E, Fendler A and Jung K:
Piwi-interacting RNAs as novel prognostic markers in clear cell
renal cell carcinomas. J Exp Clin Cancer Res. 34:612015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ljungberga B, Cowan NC, Hanbury DC, Hora
M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF and Sinescu IC:
European Association of Urology Guideline Group: EAU guidelines on
renal cell carcinoma: The 2010 update. Eur Urol. 58:398–406. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sekar RR, De La Calle CM, Patil D, Holzman
SA, Baum Y, Sheikh U, Huang JH, Osunkoya AO, Pollack BP, Kissick
HT, et al: Major histocompatibility complex I upregulation in clear
cell renal cell carcinoma is associated with increased survival.
Asian J Urol. 3:75–81. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gong J, Maia MC, Dizman N, Govindarajan A
and Pal SK: Metastasis in renal cell carcinoma: Biology and
implications for therapy. Asian J Urol. 3:286–292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zisman A, Pantuck AJ, Wieder J, Chao DH,
Dorey F, Said JW, deKernion JB, Figlin RA and Belldegrun AS: Risk
group assessment and clinical outcome algorithm to predict the
natural history of patients with surgically resected renal cell
carcinoma. J Clin Oncol. 20:4559–4566. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang B, Yin C, Li H, Shi L, Liu N, Sun Y,
Lu S, Liu Y, Sun L, Li X, et al: Nir1 promotes invasion of breast
cancer cells by binding to chemokine (C-C motif) ligand 18 through
the PI3K/Akt/GSK3β/Snail signalling pathway. Eur J Cancer.
49:3900–3913. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Q, Tang Y, Yu H, Yin Q, Li M, Shi L,
Zhang W, Li D and Li L: CCL18 from tumor-cells promotes epithelial
ovarian cancer metastasis via mTOR signaling pathway. Mol Carcinog.
55:1688–1699. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Okigaki M, Davis C, Falasca M, Harroch S,
Felsenfeld DP, Sheetz MP and Schlessinger J: Pyk2 regulates
multiple signaling events crucial for macrophage morphology and
migration. Proc Natl Acad Sci USA. 100:10740–10745. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun CK, Man K, Ng KT, Ho JW, Lim ZX, Cheng
Q, Lo CM, Poon RT and Fan ST: Proline-rich tyrosine kinase 2 (Pyk2)
promotes proliferation and invasiveness of hepatocellular carcinoma
cells through c-Src/ERK activation. Carcinogenesis. 29:2096–2105.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Y, Moschetta M, Huynh D, Tai YT,
Zhang Y, Zhang W, Mishima Y, Ring JE, Tam WF, Xu Q, et al: Pyk2
promotes tumor progression in multiple myeloma. Blood.
124:2675–2686. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lev S, Hernandez J, Martinez R, Chen A,
Plowman G and Schlessinger J: Identification of a novel family of
targets of PYK2 related to Drosophila retinal degeneration B (rdgB)
protein. Mol Cell Biol. 19:2278–2288. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun CK, Ng KT, Lim ZX, Cheng Q, Lo CM,
Poon RT, Man K, Wong N and Fan ST: Proline-rich tyrosine kinase 2
(Pyk2) promotes cell motility of hepatocellular carcinoma through
induction of epithelial to mesenchymal transition. PLoS One.
6:e188782011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Naylor TL, Greshock J, Wang Y, Colligon T,
Yu QC, Clemmer V, Zaks TZ and Weber BL: High resolution genomic
analysis of sporadic breast cancer using array-based comparative
genomic hybridization. Breast Cancer Res. 7:R1186–R1198. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wendt MK, Schiemann BJ, Parvani JG, Lee
YH, Kang Y and Schiemann WP: TGF-β stimulates Pyk2 expression as
part of an epithelial-mesenchymal transition program required for
metastatic outgrowth of breast cancer. Oncogene. 32:2005–2015.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Selitrennik M and Lev S: PYK2 integrates
growth factor and cytokine receptors signaling and potentiates
breast cancer invasion via a positive feedback loop. Oncotarget.
6:22214–22226. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kuang BH, Zhang MQ, Xu LH, Hu LJ, Wang HB,
Zhao WF, Du Y and Zhang X: Proline-rich tyrosine kinase 2 and its
phosphorylated form pY881 are novel prognostic markers for
non-small-cell lung cancer progression and patients' overall
survival. Br J Cancer. 109:1252–1263. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li Z, Yuan X, Wu Z, Guo Z, Jiang P and Wen
Z: Expressions of FAK and Pyk2 in human astrocytic tumors and their
relationship with angiogenesis. Chin-Ger J Clin Oncol. 7:658–660.
2008. View Article : Google Scholar
|
|
19
|
Yue Y, Li ZN, Fang QG, Zhang X, Yang LL,
Sun CF and Liu FY: The role of Pyk2 in the CCR7-mediated regulation
of metastasis and viability in squamous cell carcinoma of the head
and neck cells in vivo and in vitro. Oncol Rep. 34:3280–3287. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Campbell SC, Novick AC, Belldegrun A,
Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ,
Matin SF, et al: Guideline for management of the clinical T1 renal
mass. J Urol. 182:1271–1279. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cohen HT and McGovern FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Taneja SS: Re: Validation of the 2009 TNM
version in a large multi-institutional cohort of patients treated
for renal cell carcinoma: Are further improvements needed? J Urol.
185:12232011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gupta K, Miller JD, Li JZ, Russell MW and
Charbonneau C: Epidemiologic and socioeconomic burden of metastatic
renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev.
34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Motzer RJ, Bacik J, Schwartz LH, Reuter V,
Russo P, Marion S and Mazumdar M: Prognostic factors for survival
in previously treated patients with metastatic renal cell
carcinoma. J Clin Oncol. 22:454–463. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Weinstock M and McDermott D: Targeting
PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma.
Ther Adv Urol. 7:365–377. 2015. View Article : Google Scholar : PubMed/NCBI
|
